Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8744693 | Clinical Epidemiology and Global Health | 2018 | 8 Pages |
Abstract
Pioglitazone use is associated with risk of BC in T2DM patients. Risk of bladder cancer appears to be associated with higher dose and longer duration of pioglitazone use.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Mohammad Adil, Rashid Ali Khan, Pinaki Ghosh, Shiva Kumar Venkata, Amit Dattatraya Kandhare, Manju Sharma,